The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II

INTRODUCTION: Post-hoc analyses of the BIPARK-I and II trials previously demonstrated that opicapone (OPC) 50 mg was efficacious over the whole trajectory of motor fluctuation evolution in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations, with enhanced efficacy in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocha, José-Francisco, Ebersbach, Georg, Lees, Andrew, Tolosa, Eduardo, Ferreira, Joaquim J., Poewe, Werner, Rascol, Olivier, Stocchi, Fabrizio, Antonini, Angelo, Magalhães, Diogo, Gama, Helena, Soares-da-Silva, Patrício
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446144/
https://www.ncbi.nlm.nih.gov/pubmed/36081875
http://dx.doi.org/10.3389/fneur.2022.994114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446144/
https://www.ncbi.nlm.nih.gov/pubmed/36081875
http://dx.doi.org/10.3389/fneur.2022.994114

Ejemplares similares